Stock A187660 ADM KOREA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ADM Korea Inc.

Equities

A187660

KR7187660006

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3,490 KRW -2.92% Intraday chart for ADM Korea Inc. -6.56% +80.08%
Mar. 11 Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 32.47% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion. CI
2023 ADM Korea Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 129,707 43,575 44,182
Enterprise Value (EV) 1 99,272 9,146 25,899
P/E ratio 61.6 x 166 x -13.8 x
Yield - - -
Capitalization / Revenue 9.28 x 2.93 x 3.2 x
EV / Revenue 7.1 x 0.61 x 1.88 x
EV / EBITDA 35.6 x 27.6 x -13.6 x
EV / FCF -92.5 x 5.57 x -1.81 x
FCF Yield -1.08% 17.9% -55.2%
Price to Book 3.86 x 1.44 x 1.51 x
Nbr of stocks (in thousands) 21,836 21,153 22,798
Reference price 2 5,940 2,060 1,938
Announcement Date 2/28/22 3/20/23 3/18/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales 1 13,978 14,883 13,790
EBITDA 1 2,792 331 -1,906
EBIT 1 2,091 -754.7 -3,465
Operating Margin 14.96% -5.07% -25.12%
Earnings before Tax (EBT) 1 2,170 76.56 -3,308
Net income 1 1,923 266.5 -2,970
Net margin 13.75% 1.79% -21.54%
EPS 2 96.46 12.43 -140.4
Free Cash Flow 1 -1,073 1,642 -14,288
FCF margin -7.68% 11.03% -103.61%
FCF Conversion (EBITDA) - 496.02% -
FCF Conversion (Net income) - 615.99% -
Dividend per Share - - -
Announcement Date 2/28/22 3/20/23 3/18/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 - - -
Net Cash position 1 30,435 34,429 18,283
Leverage (Debt/EBITDA) - - -
Free Cash Flow 1 -1,073 1,642 -14,288
ROE (net income / shareholders' equity) 7.13% -0.17% -9.48%
ROA (Net income/ Total Assets) 4.42% -1.11% -4.79%
Assets 1 43,482 -23,915 62,076
Book Value Per Share 2 1,538 1,434 1,284
Cash Flow per Share 2 241.0 146.0 159.0
Capex 1 1,074 1,417 12,435
Capex / Sales 7.68% 9.52% 90.18%
Announcement Date 2/28/22 3/20/23 3/18/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ADM KOREA INC. Stock ADM Korea Inc.
+80.08% 53.35M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+47.02% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.95B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 11.32B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A187660 Stock
  4. Financials ADM Korea Inc.